These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 39201322)

  • 21. Targeted proteomics as a tool to detect SARS-CoV-2 proteins in clinical specimens.
    Bezstarosti K; Lamers MM; Doff WAS; Wever PC; Thai KTD; van Kampen JJA; Haagmans BL; Demmers JAA
    PLoS One; 2021; 16(11):e0259165. PubMed ID: 34762662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metaproteomics Analysis of SARS-CoV-2-Infected Patient Samples Reveals Presence of Potential Coinfecting Microorganisms.
    Thuy-Boun PS; Mehta S; Gruening B; McGowan T; Nguyen A; Rajczewski AT; Johnson JE; Griffin TJ; Wolan DW; Jagtap PD
    J Proteome Res; 2021 Feb; 20(2):1451-1454. PubMed ID: 33393790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CoVProt: Toward a Mass Spectrometry Data Portal for COVID-19 Proteomics Research and Development.
    Rajoria S; Kavuru SR; Pyda HS; Bihani S; Borishetty D; Biswas D; Prajapati J; Paladi H; Srivastava S
    OMICS; 2024 Jan; 28(1):24-31. PubMed ID: 38193774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low Volume in Vitro Diagnostic Proton NMR Spectroscopy of Human Blood Plasma for Lipoprotein and Metabolite Analysis: Application to SARS-CoV-2 Biomarkers.
    Lodge S; Nitschke P; Loo RL; Kimhofer T; Bong SH; Richards T; Begum S; Spraul M; Schaefer H; Lindon JC; Holmes E; Nicholson JK
    J Proteome Res; 2021 Feb; 20(2):1415-1423. PubMed ID: 33491459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVIDomics: The Proteomic and Metabolomic Signatures of COVID-19.
    Costanzo M; Caterino M; Fedele R; Cevenini A; Pontillo M; Barra L; Ruoppolo M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applications of Mass Spectrometry in the Characterization, Screening, Diagnosis, and Prognosis of COVID-19.
    Yamada CAO; de Paula Oliveira Santos B; Lemos RP; Batista ACS; da Conceição IMCA; de Paula Sabino A; E Lima LMTDR; de Magalhães MTQ
    Adv Exp Med Biol; 2024; 1443():33-61. PubMed ID: 38409415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Data-independent acquisition mass spectrometry for site-specific glycoproteomics characterization of SARS-CoV-2 spike protein.
    Chang D; Klein JA; Nalehua MR; Hackett WE; Zaia J
    Anal Bioanal Chem; 2021 Dec; 413(29):7305-7318. PubMed ID: 34635934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing.
    Zecha J; Lee CY; Bayer FP; Meng C; Grass V; Zerweck J; Schnatbaum K; Michler T; Pichlmair A; Ludwig C; Kuster B
    Mol Cell Proteomics; 2020 Sep; 19(9):1503-1522. PubMed ID: 32591346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of targeted mass spectrometry in bottom-up proteomics for systems biology research.
    Manes NP; Nita-Lazar A
    J Proteomics; 2018 Oct; 189():75-90. PubMed ID: 29452276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2-host proteome interactions for antiviral drug discovery.
    Liu X; Huuskonen S; Laitinen T; Redchuk T; Bogacheva M; Salokas K; Pöhner I; Öhman T; Tonduru AK; Hassinen A; Gawriyski L; Keskitalo S; Vartiainen MK; Pietiäinen V; Poso A; Varjosalo M
    Mol Syst Biol; 2021 Nov; 17(11):e10396. PubMed ID: 34709727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human bronchial-pulmonary proteomics in coronavirus disease 2019 (COVID-19) pandemic: applications and implications.
    Tan HW; Xu YM; Lau ATY
    Expert Rev Proteomics; 2021 Nov; 18(11):925-938. PubMed ID: 34812694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma/Serum Proteomics based on Mass Spectrometry.
    Zhu Y
    Protein Pept Lett; 2024; 31(3):192-208. PubMed ID: 38869039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of serum prognostic biomarkers of severe COVID-19 using a quantitative proteomic approach.
    Kimura Y; Nakai Y; Shin J; Hara M; Takeda Y; Kubo S; Jeremiah SS; Ino Y; Akiyama T; Moriyama K; Sakai K; Saji R; Nishii M; Kitamura H; Murohashi K; Yamamoto K; Kaneko T; Takeuchi I; Hagiwara E; Ogura T; Hasegawa H; Tamura T; Yamanaka T; Ryo A
    Sci Rep; 2021 Oct; 11(1):20638. PubMed ID: 34667241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study.
    Byeon SK; Madugundu AK; Garapati K; Ramarajan MG; Saraswat M; Kumar-M P; Hughes T; Shah R; Patnaik MM; Chia N; Ashrafzadeh-Kian S; Yao JD; Pritt BS; Cattaneo R; Salama ME; Zenka RM; Kipp BR; Grebe SKG; Singh RJ; Sadighi Akha AA; Algeciras-Schimnich A; Dasari S; Olson JE; Walsh JR; Venkatakrishnan AJ; Jenkinson G; O'Horo JC; Badley AD; Pandey A
    Lancet Digit Health; 2022 Sep; 4(9):e632-e645. PubMed ID: 35835712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress in understanding COVID-19: insights from the omics approach.
    Lin B; Liu J; Liu Y; Qin X
    Crit Rev Clin Lab Sci; 2021 Jun; 58(4):242-252. PubMed ID: 33375876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative Assessment of SARS-CoV-2 Virus in Nasopharyngeal Swabs Stored in Transport Medium by a Straightforward LC-MS/MS Assay Targeting Nucleocapsid, Membrane, and Spike Proteins.
    Saadi J; Oueslati S; Bellanger L; Gallais F; Dortet L; Roque-Afonso AM; Junot C; Naas T; Fenaille F; Becher F
    J Proteome Res; 2021 Feb; 20(2):1434-1443. PubMed ID: 33497234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NMR Spectroscopic Windows on the Systemic Effects of SARS-CoV-2 Infection on Plasma Lipoproteins and Metabolites in Relation to Circulating Cytokines.
    Lodge S; Nitschke P; Kimhofer T; Coudert JD; Begum S; Bong SH; Richards T; Edgar D; Raby E; Spraul M; Schaefer H; Lindon JC; Loo RL; Holmes E; Nicholson JK
    J Proteome Res; 2021 Feb; 20(2):1382-1396. PubMed ID: 33426894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneity of SARS-CoV-2 virus produced in cell culture revealed by shotgun proteomics and supported by genome sequencing.
    Gallais F; Pible O; Gaillard JC; Debroas S; Batina H; Ruat S; Sandron F; Delafoy D; Gerber Z; Olaso R; Gas F; Bellanger L; Deleuze JF; Grenga L; Armengaud J
    Anal Bioanal Chem; 2021 Dec; 413(29):7265-7275. PubMed ID: 34013402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mass Spectrometry-Based Proteomics Research to Fight COVID-19: An Expert Review on Hopes and Challenges.
    Amiri-Dashatan N; Koushki M; Rezaei-Tavirani M
    OMICS; 2022 Jan; 26(1):19-34. PubMed ID: 35005991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open Modification Searching of SARS-CoV-2-Human Protein Interaction Data Reveals Novel Viral Modification Sites.
    Adams C; Boonen K; Laukens K; Bittremieux W
    Mol Cell Proteomics; 2022 Dec; 21(12):100425. PubMed ID: 36241021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.